Fei Chen
Qixia Xu
Liu Han
Jiaqian Xu
Libin Gao
Xiaochen Sun
Yiwen Li
Yan Li
Min Qian
Yu Sun
1. Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, University of Chinese Academy of Sciences, Shanghai 200031, China
2. Institute of Health Sciences, Shanghai Jiao Tong University, School of Medicine and Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
3. Department of Medicine and VAPSHCS, University of Washington, Seattle, WA 98195, USA
Funds: This review article is dedicated to Dr. Nelly Auersperg, a pioneer physician scientist who inspired the world to systematically investigate human ovarian cancer and continues to challenge our research in multiple fields. We are grateful to Drs. Peter Nelson and Judith Campisi for inspiring discussion and insightful comments. This work was supported by grants from National Key Research and Development Program of China (2016YFC1302400), National Natural Science Foundation of China (Grant Nos. 81472709 and 31671425), the National 1000 Young Talents Research Program of China, and the U.S. Department of Defense (DoD) Prostate Cancer Research Program (PCRP) (Idea Development Award PC111703) to Y.S.
More InformationCorresponding author: Yu Sun, sunyu@sibs.ac.cn
Received Date: 2017-07-06
Accepted Date:2017-08-21
Publish Date:2018-01-01
Abstract
Abstract
Development of ovarian cancer involves the co-evolution of neoplastic cells together with the adjacent microenvironment. Steps of malignant progression including primary tumor outgrowth, therapeutic resistance, and distant metastasis are not determined solely by genetic alterations in ovarian cancer cells, but considerably shaped by the fitness advantage conferred by benign components in the ovarian stroma. As the dynamic cancer topography varies drastically during disease progression, heterologous cell types within the tumor microenvironment (TME) can actively determine the pathological track of ovarian cancer. Resembling many other solid tumor types, ovarian malignancy is nurtured by a TME whose dark side may have been overlooked, rather than overestimated. Further, harnessing breakthrough and targeting cures in human ovarian cancer requires insightful understanding of the merits and drawbacks of current treatment modalities, which mainly target transformed cells. Thus, designing novel and precise strategies that both eliminate cancer cells and manipulate the TME is increasingly recognized as a rational avenue to improve therapeutic outcome and prevent disease deterioration of ovarian cancer patients.Keywords: ovarian cancer,
stromal cells,
tumor microenvironment,
therapeutic resistance,
ectopic metastasis,
combinational treatment,
patient stratification
PDF全文下载地址:
http://www.protein-cell.org/article/exportPdf?id=b4dfd9c6-707c-4ee7-b2e2-eb8a1b2c5ce5&language=en
